High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 57, Issue 1, 2016, Pages 92-98

  Mabuchi, Ryoko ^a   Hara, Takeshi ^a   Matsumoto, Takuro ^a   Shibata, Yuhei ^a   Nakamura, Nobuhiko ^a   Nakamura, Hiroshi ^a   Kitagawa, Junichi ^a   Kanemura, Nobuhiro ^a   Goto, Naoe ^a   Shimizu, Masahito ^a   Ito, Hiroyasu ^a   Yamamoto, Yasuko ^b   Saito, Kuniaki ^b   Moriwaki, Hisataka ^a   Tsurumi, Hisashi ^a  

^a GIFU UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

3 dioxygenase; acute myeloid leukemia (AML); immunological tolerance; indoleamine 2; L kynurenine; L tryptophan catabolism; prognostic factor

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; KYNURENINE; LACTATE DEHYDROGENASE; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; INTERMEDIATE RISK PATIENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; ADOLESCENT; BLOOD; CHROMOSOME BANDING PATTERN; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REMISSION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHROMOSOME BANDING; FEMALE; HUMANS; IMMUNOPHENOTYPING; KYNURENINE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; ROC CURVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954287348     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1041388     Document Type: Article

References (48)

1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
2. Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988;27:34-37.
3. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987;5:1364-1372.
4. Greenwood MJ, Seftel MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 2006;47:1245-1252.
5. Gaidzik V, Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008;35:346-355.
6. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115-136.
7. Mrózek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-448.
8. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-473.
9. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-1372.
10. Murray HW, Szuro-Sudol A, Wellner D, et al. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun 1989;57:845-849.
11. Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFNgamma-independent mechanism. Eur J Immunol 2001;31:2313-2318.
12. Fujigaki H, Saito K, Fujigaki S, et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2, 3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 2006;139:655-662.
13. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002;196:459-468.
14. Huang A, Fuchs D, Widner B, et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-1696.
15. Yoshikawa T, Hara T, Tsurumi H, et al. Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 2010;84:304-309.
16. Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine 2, 3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011;90:409-416.
17. Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine 2, 3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2012;53:1143-1145.
18. Fukuno K, Hara T, Tsurumi H, et al. Expression of indoleamine 2, 3-dioxygenase in leukemic cells indicates an unfavorable prognosis in patients with acute myeloid leukemia and intermediate-risk cytogenetics. Leuk Lymphoma In press
19. Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow S, Campo E, Harris NL, editors. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; 2008. Pp. 124-126.
20. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
21. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-2333.
22. Fujigaki S, Saito K, Takemura M, et al. Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. Arch Biochem Biophys 1998;358:329-335.
23. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol 2003;120:56-62.
24. Tsurumi H, Kanemura N, Hara T, et al. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol 2007;133:547-553.
25. Kanemura N, Tsurumi H, Kasahara S, et al. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colonystimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematol Oncol 2008;26:33-38.
26. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
27. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
28. Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003;9:1269-1274.
29. Della Chiesa M, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood 2006;108:4118-4125.
30. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006;95:1555-1561.
31. Takao M, Okamoto A, Nikaido T, et al. Increased synthesis of indoleamine-2, 3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007;17:1333-1339.
32. Hu B, Hissong BD, Carlin JM. Interleukin-1 enhances indoleamine 2, 3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J Interferon Cytokine Res 1995;15:617-624.
33. Hissong BD, Carlin JM. Potentiation of interferon-induced indoleamine 2, 3-dioxygenase mRNA in human mononuclear phagocytes by lipopolysaccharide and interleukin-1. J Interferon Cytokine Res 1997;17:387-393.
34. Currier AR, Ziegler MH, Riley MM, et al. Tumor necrosis factor-alpha and lipopolysaccharide enhance interferon-induced antichlamydial indoleamine dioxygenase activity independently. J Interferon Cytokine Res 2000;20:369-376.
35. Babcock TA, Carlin JM. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000;12: 588-594.
36. Robinson CM, Shirey KA, Carlin JM. Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 2003;23:413-421.
37. Chon SY, Hassanain HH, Pine R, et al. Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2, 3-dioxygenase gene. J Interferon Cytokine Res 1995;15:517-526.
38. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferongamma-inducible expression of human indoleamine 2, 3-dioxygenase gene. J Biol Chem 1996;271:17247-17252.
39. Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005;25:20-30.
40. Creelan BC, Antonia S, Bepler G, et al. Indoleamine 2, 3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology 2013;2:e23428.
41. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004;114:280-290.
42. Muller AJ, DuHadaway JB, Donover PS, et al. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-319.
43. Yoshida N, Ino K, Ishida Y, et al. Overexpression of indoleamine 2, 3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 2008;14:7251-7259.
44. Inaba T, Ino K, Kajiyama H, et al. Role of the immunosuppressive enzyme indoleamine 2, 3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009;115:185-192.
45. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
46. Jeong YI, Jung ID, Lee JS, et al. (?)-Epigallocatechin gallate suppresses indoleamine 2, 3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem Biophys Res Commun 2007;354:1004-1009.
47. Cheng CW, Shieh PC, Lin YC, et al. Indoleamine 2, 3-dioxygenase, an immunomodulatory protein, is suppressed by (?)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem 2010;58:887-894.
48. Ogawa K, Hara T, Shimizu M, et al. Suppression of azoxymethaneinduced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2, 3-dioxygenase. Cancer Sci 2012;103: 951-958.